On Aug. 23, 2022, Pfizer and BioNTech announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-ﾵg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing previously reported interim vaccine efficacy data collected in March and April 2022.

Emergency Use Authorization of this vaccine was granted by the U.S. Food and Drug Administration for this age group on Jun. 17 and an application for conditional marketing authorization in this age group was under review by the European Medicines Agency.